🇺🇸 FDA
Patent

US 9562088

Pegylated CD154 peptides and methods of inhibiting CD40 interacations with CD154

granted A61KA61K38/08A61K38/10

Quick answer

US patent 9562088 (Pegylated CD154 peptides and methods of inhibiting CD40 interacations with CD154) held by The Regents of the University of Colorado, a Body Corporate expires Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 02 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K38/08, A61K38/10, A61K38/1774